Progress of bispecific antibody drugs in hematological malignancies / 白血病·淋巴瘤

ABSTRACT

In recent years, the incidence of hematological malignancies is increasing year by year, which seriously affects the quality of life of patients. Antibody drugs are the main force of modern biological products industry, accounting for more than 50% of the global biological products market, and the application prospects of bispecific antibody drugs have attracted much attention. This article reviews the role and research progress of bispecific antibody drugs in hematological malignancies.